Cited by 113COVID-19 Clinical Research StudiesLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research

The looming storm: Blood and cytokines in COVID-19

Open access
Kaur, Supreet, Bansal, Rashika, Kollimuttathuillam, Sudarsan, Gowda, Anusha Manje, Singh, Balraj, Mehta, Dhruv, Maroules, Michael·2021·Blood Reviews

Abstract

A novel coronavirus termed as COVID-19 by WHO has been the causative agent of an unprecedented pandemic in the history of humanity. The global burden of mortality and morbidity associated with this pandemic continues to increase with each passing day as it is progressively leading to multiorgan dysfunction. In most cases, the cause of death has been attributed to respiratory failure, sepsis, cardiac failure, kidney injury, or coagulopathy. As more knowledge is being unfolded, an in-depth understanding of various systemic manifestations and complications of SARS-CoV2 is vital for optimum management of these patients. This novel virus is known to spread faster than its two ancestors, the SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), demonstrating a case fatality ranging from 5 to 8% [1]. Hematological abnormalities such as lymphopenia, thrombocytopenia, elevated D-Dimer, elevated fibrinogen, elevated fibrinogen degradation products as well as cytokines such as IL-6 are emerging as important prognostic marker for worse outcome of COVID-19. Among various systemic manifestations, hematological complications such as venous thrombosis causing pulmonary embolism or deep vein thrombosis, and arterial thrombosis causing myocardial infarction, strokes or limb ischemia are being noted to be directly linked to high mortality from COVID-19. An attempt to understand the pathophysiology of various hematological abnormalities including cytokine storm, hypercoagulable state and some rare presentations of this disease hence becomes imperative. Through this review, we aim to provide an up-to-date summary of current evidence-based literature of hematological manifestations, their consequences and management including role of anticoagulation and drugs targeting cytokine storm in patients with SARS-CoV-2.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.blre.2020.100743

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 83 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. [4]COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) Available from https://coronavirus.jhu.edu/map.html 2020 PMC9432867 36057267
  2. [45]Helms J, Charles Tacquard, et al. High risk of thrombosis in patients in severe SARS-CoV-2 infection: a Multicenter prospective cohort study. Intensive Care Med DOI: 10.1007/s00134-020-06062-x. PMC7197634 32367170 · DOI
  3. [68]Huang C. Wang Y. Li X. Ren L. Zhao J. Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet. 395 2020 497 506 10.1016/S0140-6736(20)30183-5 31986264 PMC7159299 · DOI · Paper page

Cited by

Sorted by citations

Authors
Kaur, S., Bansal, R., Kollimuttathuillam, S., Gowda, A. M., Singh, B., Mehta, D., & Maroules, M.
Affiliations
  • St. Joseph’s University Medical Center (US)
  • National Institutes of Health (US)
  • Westchester Medical Center (US)
Corresponding author
Kaur, Supreet
Venue
Blood Reviews
Publisher
Elsevier BV
Published
2021-03
Volume
46
Pages
100743
ISSN
0268-960X (ISSN-L)
OpenAlex
W3049196457
Cited by
113
References
83
Citations by year
2026: 7 · 2025: 8 · 2024: 13 · 2023: 19 · 2022: 37 · 2021: 22 · 2020: 7
FWCI
1.00
Type
journal article
Language
en
Open access
Locations
  • Blood Reviews (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Touro Scholar (Touro College) (submittedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Neurology › Long-Term Effects of COVID-19
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords
COVID-19 pandemic, SARS-CoV-2, cytokine storm, hypercoagulability, thrombosis, venous thromboembolism, arterial thrombosis, lymphopenia, thrombocytopenia, D-dimer, fibrinogen, interleukin-6, anticoagulation, multiple organ failure, prognostic factors
MeSH terms
COVID-19, SARS-CoV-2, Blood Coagulation Disorders, Humans, Prognosis, Cytokines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review